Bone Biologics (NASDAQ:BBLG – Get Free Report) and Establishment Labs (NASDAQ:ESTA – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, analyst recommendations and institutional ownership.
Volatility and Risk
Bone Biologics has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500. Comparatively, Establishment Labs has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500.
Profitability
This table compares Bone Biologics and Establishment Labs’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bone Biologics | N/A | -124.71% | -111.64% |
| Establishment Labs | -46.13% | -184.55% | -24.81% |
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bone Biologics | N/A | N/A | -$8.95 million | N/A | N/A |
| Establishment Labs | $153.07 million | 7.32 | -$78.50 million | ($2.58) | -15.51 |
Bone Biologics has higher earnings, but lower revenue than Establishment Labs.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Bone Biologics and Establishment Labs, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bone Biologics | 0 | 0 | 0 | 0 | 0.00 |
| Establishment Labs | 0 | 1 | 3 | 1 | 3.00 |
Establishment Labs has a consensus price target of $60.60, indicating a potential upside of 51.46%. Given Establishment Labs’ stronger consensus rating and higher possible upside, analysts plainly believe Establishment Labs is more favorable than Bone Biologics.
Insider & Institutional Ownership
34.3% of Bone Biologics shares are held by institutional investors. Comparatively, 72.9% of Establishment Labs shares are held by institutional investors. 7.5% of Bone Biologics shares are held by company insiders. Comparatively, 11.4% of Establishment Labs shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Establishment Labs beats Bone Biologics on 9 of the 12 factors compared between the two stocks.
About Bone Biologics
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
About Establishment Labs
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.
Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
